Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism

Next Previous
Trial Profile

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eneboparatide (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions; First in man
  • Sponsors Amolyt Pharma

Most Recent Events

  • 23 Sep 2022 Status changed from active, no longer recruiting to completed.
  • 01 Jun 2022 Results from first cohort published in an Amolyt Pharma Media Release.
  • 01 Jun 2022 According to an Amolyt Pharma media release, detailed data from cohort 1 will be presented at an upcoming medical conference later this year and full data is expected in fall 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top